Thermo Fisher Scientific Capabilities Update August 2026: Oral Solid Dose Formulation

Developing successful oral solid dose (OSD) therapies requires overcoming formulation challenges that can affect bioavailability, stability, manufacturability, and development timelines. This presentation will explore common formulation hurdles and strategies for addressing them through scientific expertise and innovative development approaches while highlighting how Thermo Fisher Scientific partners with customers to accelerate programs from development through clinical manufacturing.

Viewers will also learn about Thermo Fisher's comprehensive end-to-end OSD capabilities — including formulation and analytical development, process development, clinical and commercial manufacturing, technology transfer, and regulatory support — which help sponsors reduce risk, streamline development, and bring therapies to patients faster without compromising quality.